TREATMENT OF TUMORS EXPRESSING MUTANT P53
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Feb 9, 2017
app pub date -
Jan 8, 2015
filing date -
Jan 9, 2014
priority date (Note) -
Published
status (Latency Note)
Importance
|
US Family Size
|
Non-US Coverage
|
Abstract
PDGFRb inhibitors and the use of such inhibitors to treat mutant p53-expressing tumors are described. The present disclosure encompasses the discovery that mutant p53-induced upregulation of the platelet-derived growth factor receptor b (PDGFRb) contributes to invasion and/or metastasis of tumors expressing mutant p53. Specifically, the present disclosure encompasses the discovery that mutant p53 can disrupt a p73/NF-Y complex (which can repress PDGFRB transcription), leading to transcription of PDGFRb. The present disclosure therefore provides, at least in part, PDGFRb modulators (e.g., activators or inhibitors) for use in medicine, and specifically in diagnosis, treatment and/or prevention (e.g., delay of onset) of certain disorders, e.g., cancer.
First Claim
Other Claims data not available
Family
| Country | kind | publication No. | Filing Date |
|---|---|---|---|
| AU | A1 | AU2015204767 | Jan 08, 2015 |
| EP | B1 | EP3092492 | Jan 08, 2015 |
| CA | A1 | CA2936254 | Jan 08, 2015 |
| WO | A2 | WO2015105996 | Jan 08, 2015 |
International Classification(s)
- 2015 Application Filing Year
- A61K Class
- 16157 Applications Filed
- 11882 Patents Issued To-Date
- 73.55 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 8 Age